Literature DB >> 21059987

Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.

Kyle B Womack1, Ramon Diaz-Arrastia, Howard J Aizenstein, Steven E Arnold, Nancy R Barbas, Bradley F Boeve, Christopher M Clark, Charles S DeCarli, William J Jagust, James B Leverenz, Elaine R Peskind, R Scott Turner, Edward Y Zamrini, Judith L Heidebrink, James R Burke, Steven T DeKosky, Martin R Farlow, Matthew J Gabel, Roger Higdon, Claudia H Kawas, Robert A Koeppe, Anne M Lipton, Norman L Foster.   

Abstract

OBJECTIVE: To evaluate the cause of diagnostic errors in the visual interpretation of positron emission tomographic scans with fludeoxyglucose F 18 (FDG-PET) in patients with frontotemporal lobar degeneration (FTLD) and patients with Alzheimer disease (AD).
DESIGN: Twelve trained raters unaware of clinical and autopsy information independently reviewed FDG-PET scans and provided their diagnostic impression and confidence of either FTLD or AD. Six of these raters also recorded whether metabolism appeared normal or abnormal in 5 predefined brain regions in each hemisphere-frontal cortex, anterior cingulate cortex, anterior temporal cortex, temporoparietal cortex, and posterior cingulate cortex. Results were compared with neuropathological diagnoses.
SETTING: Academic medical centers. PATIENTS: Forty-five patients with pathologically confirmed FTLD (n=14) or AD (n=31).
RESULTS: Raters had a high degree of diagnostic accuracy in the interpretation of FDG-PET scans; however, raters consistently found some scans more difficult to interpret than others. Unanimity of diagnosis among the raters was more frequent in patients with AD (27 of 31 patients [87%]) than in patients with FTLD (7 of 14 patients [50%]) (P=.02). Disagreements in interpretation of scans in patients with FTLD largely occurred when there was temporoparietal hypometabolism, which was present in 7 of the 14 FTLD scans and 6 of the 7 scans lacking unanimity. Hypometabolism of anterior cingulate and anterior temporal regions had higher specificities and positive likelihood ratios for FTLD than temporoparietal hypometabolism had for AD.
CONCLUSIONS: Temporoparietal hypometabolism in FTLD is common and may cause inaccurate interpretation of FDG-PET scans. An interpretation paradigm that focuses on the absence of hypometabolism in regions typically affected in AD before considering FTLD is likely to misclassify a significant portion of FTLD scans. Anterior cingulate and/or anterior temporal hypometabolism indicates a high likelihood of FTLD, even when temporoparietal hypometabolism is present. Ultimately, the accurate interpretation of FDG-PET scans in patients with dementia cannot rest on the presence or absence of a single region of hypometabolism but rather must take into account the relative hypometabolism of all brain regions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21059987      PMCID: PMC3058918          DOI: 10.1001/archneurol.2010.295

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  51 in total

1.  Telling the difference between frontotemporal dementia and Alzheimer's disease.

Authors:  Florence Pasquier
Journal:  Curr Opin Psychiatry       Date:  2005-11       Impact factor: 4.741

2.  Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.

Authors:  Mario F Mendez; Jill S Shapira; Aaron McMurtray; Eliot Licht
Journal:  Am J Geriatr Psychiatry       Date:  2007-01       Impact factor: 4.105

3.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

4.  Pathologically proven frontotemporal dementia presenting with severe amnesia.

Authors:  Andrew Graham; Rhys Davies; John Xuereb; Glenda Halliday; Jillian Kril; Helen Creasey; Kim Graham; John Hodges
Journal:  Brain       Date:  2005-01-05       Impact factor: 13.501

5.  Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia.

Authors:  A R Varma; J S Snowden; J J Lloyd; P R Talbot; D M Mann; D Neary
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

6.  Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy.

Authors:  Adam L Boxer; Michael D Geschwind; Nataliya Belfor; Maria Luisa Gorno-Tempini; Guido F Schauer; Bruce L Miller; Michael W Weiner; Howard J Rosen
Journal:  Arch Neurol       Date:  2006-01

7.  Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  G D Rabinovici; W W Seeley; E J Kim; M L Gorno-Tempini; K Rascovsky; T A Pagliaro; S C Allison; C Halabi; J H Kramer; J K Johnson; M W Weiner; M S Forman; J Q Trojanowski; S J Dearmond; B L Miller; H J Rosen
Journal:  Am J Alzheimers Dis Other Demen       Date:  2007 Dec-2008 Jan       Impact factor: 2.035

8.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

Review 9.  Disease-modifying therapies in Alzheimer's disease.

Authors:  Stephen Salloway; Jacobo Mintzer; Myron F Weiner; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2008-02-20       Impact factor: 21.566

10.  Clinical and pathological characterization of progressive aphasia.

Authors:  Jonathan A Knibb; John H Xuereb; Karalyn Patterson; John R Hodges
Journal:  Ann Neurol       Date:  2006-01       Impact factor: 10.422

View more
  27 in total

Review 1.  Translational research in neurology: dementia.

Authors:  Lawrence S Honig
Journal:  Arch Neurol       Date:  2012-08

Review 2.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

3.  Visual and statistical analysis of ¹⁸F-FDG PET in primary progressive aphasia.

Authors:  Jordi A Matías-Guiu; María Nieves Cabrera-Martín; María Jesús Pérez-Castejón; Teresa Moreno-Ramos; Cristina Rodríguez-Rey; Rocío García-Ramos; Aida Ortega-Candil; Marta Fernandez-Matarrubia; Celia Oreja-Guevara; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

Review 4.  Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.

Authors:  Nasim Sheikh-Bahaei; Seyed Ahmad Sajjadi; Aimee L Pierce
Journal:  Curr Treat Options Neurol       Date:  2017-11-14       Impact factor: 3.598

5.  Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

Authors:  G D Rabinovici; H J Rosen; A Alkalay; J Kornak; A J Furst; N Agarwal; E C Mormino; J P O'Neil; M Janabi; A Karydas; M E Growdon; J Y Jang; E J Huang; S J Dearmond; J Q Trojanowski; L T Grinberg; M L Gorno-Tempini; W W Seeley; B L Miller; W J Jagust
Journal:  Neurology       Date:  2011-11-30       Impact factor: 9.910

Review 6.  Neuroimaging in frontotemporal lobar degeneration--predicting molecular pathology.

Authors:  Jennifer L Whitwell; Keith A Josephs
Journal:  Nat Rev Neurol       Date:  2012-01-31       Impact factor: 42.937

Review 7.  Diagnosis and management of behavioral variant frontotemporal dementia.

Authors:  Peter S Pressman; Bruce L Miller
Journal:  Biol Psychiatry       Date:  2013-11-13       Impact factor: 13.382

8.  Diagnostic performance of an automated analysis software for the diagnosis of Alzheimer's dementia with 18F FDG PET.

Authors:  Sasan Partovi; Roger Yuh; Sara Pirozzi; Ziang Lu; Spencer Couturier; Ulrich Grosse; Mark D Schluchter; Aaron Nelson; Robert Jones; James K O'Donnell; Peter Faulhaber
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-01-15

Review 9.  Clinical phenotypes and genetic biomarkers of FTLD.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

10.  Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

Authors:  Samantha Galluzzi; Cristina Geroldi; Giovanni Amicucci; Luisella Bocchio-Chiavetto; Matteo Bonetti; Cristian Bonvicini; Maria Cotelli; Roberta Ghidoni; Barbara Paghera; Orazio Zanetti; Giovanni B Frisoni
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.